OXT and Prader-Willi syndrome: No other identified studies investigated the efficacy of oxytocin for rare MC4R pathway diseases; however, the SLR identified 4 clinical trials that investigated the efficacy of intranasal oxytocin for improving satiety in patients with PWS, with varied outcomes.